IDWEEK 2017

The patients in the study were placed into 2 groups based on their eGFR at the time of switching agents: the early-switch group (eGFR of ≥60mL/min) and the late-switch group (eGFR <60mL/min).

The safety and efficacy of two commonly used treatment regimens were assessed among patients with HCV genotype and eGFR estimations at baseline and ≥12 week after start of treatment.

The exposure-adjusted incidence rate (IR) and relative rate (RR) of both MI and CAD were compared in patients receiving ABC-containing cART to those receiving non ABC-containing cART.

The composition of the developing gut microbiome is thought to have crucial roles in maturation of the immune system.

Differences in total daily dose, AUC24, and AUC24/MIC were the primary endpoints of the study. Secondary endpoints assessed adverse events.

Dalbavancin is a lipoglycopeptide used to treat gram-positive pathogens that cause ABSSSI. In the study patients were randomized 1:1 to receive intravenous single- or 2-dose dalbavancin (1500mg IV or 1000mg on Day 1 and 500mg on Day 8).

CDI represent an “urgent threat”, but there are currently no FDA-approved drugs or vaccines to prevent infections.

Data was compiled from electronic records for patients aged 3 months to 18 years who were diagnosed with CAP between 2009 and 2013.

A total of 7 male, critically ill trauma patients with preserved renal function were included in the study and received 750mg of levofloxacin administered intravenously every 24 hours.